With nerandomilast and other novel targeted treatments in the pipeline, pulmonary fibrosis management is set for significant change, with implications for rheumatological practice. A/Prof Nicole Goh and Dr Melissa Simonds discuss the potential of this emerging landscape to shape new thinking on risk identification, earlier diagnosis, monitoring and outcomes.

Click on the video control bar to go to specific chapters

Please help assess the value of this video by completing a brief anonymous survey.

This video was created independently by the limbic. All content was developed by the presenters and views are those of the presenters alone.

Thank you to Boehringer Ingelheim for providing the unrestricted educational grant that made this project possible.